159 related articles for article (PubMed ID: 25823785)
1. FcGR genetic polymorphisms and the response to adalimumab in patients with rheumatoid arthritis.
Dávila-Fajardo CL; van der Straaten T; Baak-Pablo R; Medarde Caballero C; Cabeza Barrera J; Huizinga TW; Guchelaar HJ; Swen JJ
Pharmacogenomics; 2015; 16(4):373-81. PubMed ID: 25823785
[TBL] [Abstract][Full Text] [Related]
2. Influence of variants of Fc gamma receptors IIA and IIIA on the American College of Rheumatology and European League Against Rheumatism responses to anti-tumour necrosis factor alpha therapy in rheumatoid arthritis.
Cañete JD; Suárez B; Hernández MV; Sanmartí R; Rego I; Celis R; Moll C; Pinto JA; Blanco FJ; Lozano F
Ann Rheum Dis; 2009 Oct; 68(10):1547-52. PubMed ID: 18930989
[TBL] [Abstract][Full Text] [Related]
3. FCGR polymorphisms in the treatment of rheumatoid arthritis with Fc-containing TNF inhibitors.
Montes A; Perez-Pampin E; Joven B; Carreira P; Fernández-Nebro A; Del Carmen Ordóñez M; Navarro-Sarabia F; Moreira V; Vasilopoulos Y; Sarafidou T; Caliz R; Ferrer MA; Cañete JD; de la Serna AR; Magallares B; Narváez J; Gómez-Reino JJ; Gonzalez A
Pharmacogenomics; 2015; 16(4):333-45. PubMed ID: 25823782
[TBL] [Abstract][Full Text] [Related]
4. FCGR2A/FCGR3A Gene Polymorphisms and Clinical Variables as Predictors of Response to Tocilizumab and Rituximab in Patients With Rheumatoid Arthritis.
Jiménez Morales A; Maldonado-Montoro M; Martínez de la Plata JE; Pérez Ramírez C; Daddaoua A; Alarcón Payer C; Expósito Ruiz M; García Collado C
J Clin Pharmacol; 2019 Apr; 59(4):517-531. PubMed ID: 30457672
[TBL] [Abstract][Full Text] [Related]
5. Association of FCGR2A with the response to infliximab treatment of patients with rheumatoid arthritis.
Montes A; Perez-Pampin E; Narváez J; Cañete JD; Navarro-Sarabia F; Moreira V; Fernández-Nebro A; Del Carmen Ordóñez M; de la Serna AR; Magallares B; Vasilopoulos Y; Sarafidou T; Caliz R; Ferrer MA; Joven B; Carreira P; Gómez-Reino JJ; Gonzalez A
Pharmacogenet Genomics; 2014 May; 24(5):238-45. PubMed ID: 24667440
[TBL] [Abstract][Full Text] [Related]
6. Associations between PTPRC rs10919563 A/G and FCGR2A R131H polymorphisms and responsiveness to TNF blockers in rheumatoid arthritis: a meta-analysis.
Lee YH; Bae SC
Rheumatol Int; 2016 Jun; 36(6):837-44. PubMed ID: 27074847
[TBL] [Abstract][Full Text] [Related]
7. FCGR2A/CD32A and FCGR3A/CD16A variants and EULAR response to tumor necrosis factor-α blockers in psoriatic arthritis: a longitudinal study with 6 months of followup.
Ramírez J; Fernández-Sueiro JL; López-Mejías R; Montilla C; Arias M; Moll C; Alsina M; Sanmarti R; Lozano F; Cañete JD
J Rheumatol; 2012 May; 39(5):1035-41. PubMed ID: 22467926
[TBL] [Abstract][Full Text] [Related]
8. Confirmation of -174G/C interleukin-6 gene promoter polymorphism as a genetic marker predicting antitumor necrosis factor treatment outcome.
Dávila-Fajardo CL; Márquez A; Pascual-Salcedo D; Moreno Ramos MJ; García-Portales R; Magro C; Alegre-Sancho JJ; Balsa A; Cabeza-Barrera J; Raya E; Martín J
Pharmacogenet Genomics; 2014 Jan; 24(1):1-5. PubMed ID: 24253594
[TBL] [Abstract][Full Text] [Related]
9. Comparison of long-term clinical outcome with etanercept treatment and adalimumab treatment of rheumatoid arthritis with respect to immunogenicity.
Krieckaert CL; Jamnitski A; Nurmohamed MT; Kostense PJ; Boers M; Wolbink G
Arthritis Rheum; 2012 Dec; 64(12):3850-5. PubMed ID: 22933315
[TBL] [Abstract][Full Text] [Related]
10. Association between anti-tumour necrosis factor treatment response and genetic variants within the TLR and NF{kappa}B signalling pathways.
Potter C; Cordell HJ; Barton A; Daly AK; Hyrich KL; Mann DA; Morgan AW; Wilson AG; ; Isaacs JD
Ann Rheum Dis; 2010 Jul; 69(7):1315-20. PubMed ID: 20448286
[TBL] [Abstract][Full Text] [Related]
11. The 158VV Fcgamma receptor 3A genotype is associated with response to rituximab in rheumatoid arthritis: results of an Italian multicentre study.
Quartuccio L; Fabris M; Pontarini E; Salvin S; Zabotti A; Benucci M; Manfredi M; Biasi D; Ravagnani V; Atzeni F; Sarzi-Puttini P; Morassi P; Fischetti F; Tomietto P; Bazzichi L; Saracco M; Pellerito R; Cimmino M; Schiavon F; Carraro V; Semeraro A; Caporali R; Cavagna L; Bortolotti R; Paolazzi G; Govoni M; Bombardieri S; De Vita S
Ann Rheum Dis; 2014 Apr; 73(4):716-21. PubMed ID: 23505228
[TBL] [Abstract][Full Text] [Related]
12. FCGR2A, FCGR3A, FCGR3B polymorphisms and susceptibility to rheumatoid arthritis: a meta-analysis.
Lee YH; Bae SC; Song GG
Clin Exp Rheumatol; 2015; 33(5):647-54. PubMed ID: 26314337
[TBL] [Abstract][Full Text] [Related]
13. Fcγ receptor type IIIA polymorphism influences treatment outcomes in patients with rheumatoid arthritis treated with rituximab.
Ruyssen-Witrand A; Rouanet S; Combe B; Dougados M; Le Loët X; Sibilia J; Tebib J; Mariette X; Constantin A
Ann Rheum Dis; 2012 Jun; 71(6):875-7. PubMed ID: 22368231
[TBL] [Abstract][Full Text] [Related]
14. Impact of FCGR2A R131H, FCGR3A F158V and FCGR3B NA1/NA2 polymorphisms on response to Fc-containing TNF inhibitors in Tunisian rheumatoid arthritis patients.
Mahmoud I; Moalla M; Ben Tekaya A; Bouden S; Rouached L; Tekaya R; Saidane O; Gorji Y; Elleuch M; Laatar A; Hamdi W; Abdelmoula L; Sfar I
Drug Metab Pers Ther; 2023 Jun; 38(2):155-162. PubMed ID: 36919284
[TBL] [Abstract][Full Text] [Related]
15. Pathway analysis to identify genetic variants associated with efficacy of adalimumab in rheumatoid arthritis.
Eektimmerman F; Swen JJ; Böhringer S; Huizinga TW; Kooloos WM; Allaart CF; Guchelaar HJ
Pharmacogenomics; 2017 Jul; 18(10):945-953. PubMed ID: 28639493
[TBL] [Abstract][Full Text] [Related]
16. Variation at FCGR2A and functionally related genes is associated with the response to anti-TNF therapy in rheumatoid arthritis.
Avila-Pedretti G; Tornero J; Fernández-Nebro A; Blanco F; González-Alvaro I; Cañete JD; Maymó J; Alperiz M; Fernández-Gutiérrez B; Olivé A; Corominas H; Erra A; Aterido A; López Lasanta M; Tortosa R; Julià A; Marsal S
PLoS One; 2015; 10(4):e0122088. PubMed ID: 25848939
[TBL] [Abstract][Full Text] [Related]
17. Rheumatoid arthritis risk allele PTPRC is also associated with response to anti-tumor necrosis factor alpha therapy.
Cui J; Saevarsdottir S; Thomson B; Padyukov L; van der Helm-van Mil AH; Nititham J; Hughes LB; de Vries N; Raychaudhuri S; Alfredsson L; Askling J; Wedrén S; Ding B; Guiducci C; Wolbink GJ; Crusius JB; van der Horst-Bruinsma IE; Herenius M; Weinblatt ME; Shadick NA; Worthington J; Batliwalla F; Kern M; Morgan AW; Wilson AG; Isaacs JD; Hyrich K; Seldin MF; Moreland LW; Behrens TW; Allaart CF; Criswell LA; Huizinga TW; Tak PP; Bridges SL; Toes RE; Barton A; Klareskog L; Gregersen PK; Karlson EW; Plenge RM
Arthritis Rheum; 2010 Jul; 62(7):1849-61. PubMed ID: 20309874
[TBL] [Abstract][Full Text] [Related]
18. Fcgamma receptor type IIIA genotype and response to tumor necrosis factor alpha-blocking agents in patients with rheumatoid arthritis.
Kastbom A; Bratt J; Ernestam S; Lampa J; Padyukov L; Söderkvist P; Skogh T
Arthritis Rheum; 2007 Feb; 56(2):448-52. PubMed ID: 17265480
[TBL] [Abstract][Full Text] [Related]
19. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry.
Hetland ML; Christensen IJ; Tarp U; Dreyer L; Hansen A; Hansen IT; Kollerup G; Linde L; Lindegaard HM; Poulsen UE; Schlemmer A; Jensen DV; Jensen S; Hostenkamp G; Østergaard M;
Arthritis Rheum; 2010 Jan; 62(1):22-32. PubMed ID: 20039405
[TBL] [Abstract][Full Text] [Related]
20. Association between the functional FCGR3A F158V and FCGR2A R131H polymorphisms and responsiveness to biologics in rheumatoid arthritis patients: A meta-analysis.
Lee YH; Song GG
Int J Rheum Dis; 2023 Jul; 26(7):1295-1304. PubMed ID: 37114884
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
